Started in 20-month-old female mice, the drug matched many benefits of calorie restriction and beat it on spatial memory and glucose control, the authors report.
Recap by typeshit. Full story at Новости GxP.
Avi Roy points out that the largest test so far found no memory benefit from the drug in Ozempic, despite hopes raised by health record studies.
Balwinder Singh and Raman Baweja link GLP-1 use to less kidney replacement therapy in bipolar patients with CKD, and flag lithium toxicity cases.
Yale Medicine says 5% to 10% of people on GLP-1 weight loss drugs see little result, and points to diet as one factor that can blunt the effect.
24:26
A doctor's explainer sorting peptides into eight broad categories. An evergreen overview for anyone still learning the basics.
15:57
A video on Chinese supply behind the peptide trend and the open question of what is actually in the vials people buy.
L'Oréal's CEO told investors GLP-1s are shifting skincare buying, while Carlsberg and Diageo play down any hit to beer demand.
Loading…